Company intelligence / Profile preview

Ocunova

Harrisburg, Pennsylvania, United States

Ownership: Private
Employees: ~3
Development stage: Other

Overview

Ocunova is developing OCU-001, a repurposed naltrexone-based small‑molecule eye drop for diabetic dry eye syndrome; the company has completed early clinical work showing activity in diabetics with dry eye and is raising capital for a Phase 2/2b efficacy study in dry eye disease, including diabetic dry eye and neurotrophic keratitis.[1][2][4][5][8]

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Partnerships

Penn State College of Medicine / Penn State Medical Center (technology origin and IP licensing)[2][5]Life Sciences Greenhouse of Central Pennsylvania (LSGCP) – seed/early funding partner[2][6][8]Ben Franklin Technology Partners of Central and Northern Pennsylvania – seed/early funding partner[2][5][6][8]

Beyond the preview

Go deeper on Ocunova.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ocunova.

Explore the full profile